Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
The identification of new targets to address unmet medical needs, better in a personalized way, is an urgent necessity. The introduction of PARP1 inhibitors into therapy, almost ten years ago, has represented a step forward this need being an innovate cancer treatment through a precision medicine ap...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2023-08-01
|
| Seri Bilgileri: | Molecules |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1420-3049/28/15/5849 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|